Figure 3
![Figure 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Falzrt160/MediaObjects/13195_2012_Article_134_Fig3_HTML.jpg)
Proportion of patients showing marked clinical worsening (ITT set, LOCF analysis). aModerate to severe AD (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day). bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). *P < 0.01 versus placebo added to donepezil; **P < 0.001 versus placebo added to donepezil. AD, Alzheimer's disease; ITT, intention-to-treat; LOCF, last observation carried forward.